Abstract Backgrounds and Aims Glucagon-like-peptides 1 receptor analogues (GLP1-RAs) have gained primacy in the management of type 2 diabetes (T2D). However, in contrast to the CVOT conducted with sodium glucose cotransporter-2 inhibitors (SGLT-2i) there was a significant reduction in glycated haemoglobin (HbA1c) in some of the CVOT with GLP1-RA. The aim of this analysis is to explore the possible association between cardiovascular outcome benefits with GLP1-RA and HbA1c reduction.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with JC
Contact JC, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack